Fujifilm Launches $60 Million Vc Fund For Early-Stage Biotech

Tokyo-Based Fujifilm Announced That It Has Launched A Strategic Life Sciences Investment Fund.Fujifilm Kicked Off The Fund With An Initial Investment Of 7 Billion Jpy (Approximately $60 Million). The Fund Will Be Used To Target Partnerships With Promising Early-Stage Biotechnology Companies To Enhance Fujifilm'S Life Sciences Portfolio. "Fujifilm Is Considering A Wide Range Of New And Innovative Business Constructs In Order To Cultivate And Foster Relationships With Emerging Biotechs To Create New, And Strengthen Existing, Businesses," The Company Said In A Press Release. The Fund Will Be Managed By The Life Sciences Corporate Venture Capital (Ls-Cvc), A New Group Established Within Fujifilm'S Life Sciences Strategy Headquarters In Tokyo. The Life Sciences Strategy Headquarters Was Launched In April 2021, Designed To Plan And Promote An Integrated Strategy To Accelerate Business Growth In Life Sciences. The Life Sciences Strategy Headquarters Is In Charge Of Managing And Spending The Fund'S Resources And Creating A Business Development Timeline With Biotech Startups. The Ls-Cvc'S Mission Is To Accelerate Business Growth Within The Life Sciences Industry, Specifically Through Contract Biopharmaceutical Development And Manufacturing, Drug Discovery Research Markets And Industrial Cell Culture Media. Starting With Fujifilm'S Life Science Strategic Business Offices In Dusseldorf, Germany And Cambridge, Massachusetts, The Company Will Reach Out To Early-Stage Biotechnology Companies To Offer Funding Deals And Partnerships. In Addition To Managing This New Fund, The Venture Capital Group Will Also Now Be Managing Fujifilm'S Entire Life Science Investment Portfolio. "In Many Cases, Early-Stage Companies Are The First To Develop Cutting-Edge Technologies And Innovative Business Models. I Believe Ls-Cvc Activities Will Enable Us To Speedily Develop New Partnerships With Such Promising Companies And To Deliver Value To Society Through Innovative Products," Said Takatoshi Ishikawa, General Manager Of Fujifilm'S Life Sciences Strategy Headquarters. For Many People Worldwide, Fujifilm'S Brand Is Associated With Their Photography Business That Started In 1934. However, In The 1980S, Fujifilm Started Using Their Digital Technologies For Medical Applications, Starting With Computed Radiography. The Company Is Now A Global Leader In Several Life Sciences Markets, Including Photoacoustic Imaging, Spina Bifida Therapies, Recombinant Cell Culture Supplements, Assisted Reproductive Technology And Synapse And Cardiology Imaging Solutions, The Latter Of Which Fujifilm Was Ranked "Best In Klas" For Its Three Synapse

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!